Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Forbes

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|September 23, 1998
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG)J Bernhard, C Hürny, A S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIIA Wallgren, M Bonetti, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2012
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group reportP Karlsson, B F Cole, B H Chua, et al.
British Journal of Cancer|November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerJ Bernhard, D Zahrieh, J J Zhang, et al.
Breast (Edinburgh, Scotland)|January 8, 2014
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)N McCarthy, F Boyle, N Zdenkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1996
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study GroupG Marini, S Murray, A Goldhirsch, et al.
British Journal of Cancer|November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancerJ Bernhard, D Zahrieh, A S Coates, et al.
Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|September 23, 1998
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG)J Bernhard, C Hürny, A S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIIA Wallgren, M Bonetti, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2012
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group reportP Karlsson, B F Cole, B H Chua, et al.
British Journal of Cancer|November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerJ Bernhard, D Zahrieh, J J Zhang, et al.
Breast (Edinburgh, Scotland)|January 8, 2014
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)N McCarthy, F Boyle, N Zdenkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1996
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study GroupG Marini, S Murray, A Goldhirsch, et al.
British Journal of Cancer|November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancerJ Bernhard, D Zahrieh, A S Coates, et al.
Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.
Pageof 11